Evidence-driven strategies are reducing treatment intensity while improving outcomes and fertility preservation options.
Video Highlights
Treatment strategies have evolved from highly aggressive surgical approaches to more tailored, molecularly driven therapies, reducing morbidity while preserving oncologic outcomes.
Evidence supports laparoscopic/robotic surgery and sentinel lymph node mapping as safe alternatives to open surgery and full lymphadenectomy, significantly lowering complications such as lymphedema.
Emerging data demonstrate that tumor genomics (e.g., POLE, MMR status, p53) can guide both de-escalation and escalation strategies, improving personalization of care.
Hormonal therapies (e.g., progestins, IUDs) allow carefully selected patients—particularly those with low-grade, early-stage disease—to preserve fertility without immediate hysterectomy.
Studies such as ENDO-3 and PORTEC-4a are evaluating whether further de-escalation (including omission of nodal assessment or radiation) can be safely implemented in selected populations.
Houston Methodist gynecologic oncologists discuss evidence-based de-escalation strategies across endometrial, ovarian and cervical cancers, including minimally invasive surgery, sentinel lymph node mapping and molecular profiling. Clinical trial updates — including ENDO-3, PORTEC-4a, SHAPE and ConCerv — highlight how precision approaches are reducing surgical morbidity while preserving oncologic outcomes. Experts also address fertility-sparing management, neoadjuvant chemotherapy for advanced ovarian cancer and the expanding role of immunotherapy and targeted therapy in recurrent disease.